CPA
ROIV icon

Capital Performance Advisors’s Roivant Sciences ROIV Stock Holding History

Capital Performance Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,000
Closed -$11.5K – 2149
2024
Q3 		$11.5K Buy
+1,000
New +$11.4K ﹤0.01% 781

Other funds holding ROIV

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Capital Performance Advisors's ROIV Position: Q4 2024 in Review

Capital Performance Advisors sold out of Roivant Sciences (ROIV) in Q4 2024, closing a stake of 1,000 shares — an estimated $11.5K sold.

Capital Performance Advisors first reported a position in ROIV in Q3 2024 and held it in 1 quarter. The position peaked at $11.5K in Q3 2024. 318 funds tracked by Wall St. Rank hold ROIV as of Q4 2024.

  • Capital Performance Advisors reported no remaining Roivant Sciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 1,000 Roivant Sciences shares in Q4 2024, an estimated $11.5K.
  • Capital Performance Advisors first reported a position in Roivant Sciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Roivant Sciences position peaked at $11.5K in Q3 2024.
  • 318 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.